Improvement in the Anticancer Activity of 6-Mercaptopurine via Combination with Bismuth(Ⅲ)

DOI Web Site Web Site PubMed 参考文献23件
  • Yang Yang
    University of Shanghai for Science and Technology
  • Zhou Shuang
    Cancer Institute, Tongji University School of Medicine
  • Ouyang Ruizhuo
    University of Shanghai for Science and Technology
  • Yang Yaoqin
    Cancer Institute, Tongji University School of Medicine
  • Tao Huihong
    Cancer Institute, Tongji University School of Medicine
  • Feng Kai
    University of Shanghai for Science and Technology
  • Zhang Xiaoshen
    Cancer Institute, Tongji University School of Medicine
  • Xiong Fei
    University of Shanghai for Science and Technology
  • Guo Ning
    University of Shanghai for Science and Technology
  • Zong Tianyu
    University of Shanghai for Science and Technology
  • Cao Penghui
    University of Shanghai for Science and Technology
  • Li Yuhao
    University of Shanghai for Science and Technology
  • Miao Yuqing
    University of Shanghai for Science and Technology

書誌事項

タイトル別名
  • Improvement in the Anticancer Activity of 6-Mercaptopurine <i>via</i> Combination with Bismuth(III)

この論文をさがす

抄録

<p>6-Mercaptopurine (6-MP) is a clinically important antitumor drug and its commercially available form is provided as monohydrate, belonging to biopharmaceuticals classification system (BCS) class II category. The combination of bismuth(III) (Bi(III)) with 6-MP was proved to significantly improve the anticancer activity of 6-MP, leading to the discovery of a new amorphous complex ([Bi(MP)3(NO3)2]NO3). The prepared [Bi(MP)3(NO3)2]NO3 was characterized by the matrix assisted laser desorption-ionization time-of-flight (MALDI-TOF)-MS, etc. Noticeably, according to the in vitro evaluations of cytotoxicity, cellular apoptotic, colony formation as well as cell migration, the anticancer activity of amorphous [Bi(MP)3(NO3)2]NO3 was found to be of high therapeutic effect over 6-MP.</p>

収録刊行物

参考文献 (23)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ